title: Pharmaceutical Approval Update.
abstract: Cabozantinib (Cabometyx) for advanced renal cell carcinoma; glycopyrrolate/formoterol fumarate (Bevespi Aerosphere) for chronic obstructive pulmonary disease; and ephedrine sulfate (Akovaz) for hypotension during anesthesia.
authors.forename: Mary
authors.initials: M
authors.lastname: Choy